Phase II Efficacy and Safety of Taro Pharmaceuticals' Pro-Drug T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric Acid) in Patients With Essential Tremor: An Open-Label Dose Continuation Study.
Phase of Trial: Phase II
Latest Information Update: 26 Dec 2013
At a glance
- Drugs T 2000 (Primary)
- Indications Essential tremor
- Focus Therapeutic Use
- Sponsors Taro Pharmaceuticals USA
- 26 Dec 2013 Actual end date added as 1 December 2009 as reported in ClinicalTrials.gov record.
- 26 Dec 2013 Status changed from suspended to discontinued as reported in ClinicalTrials.gov record.
- 06 May 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.